ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $993 | $1,716 | $1,234 | $1,033 |
| - Cash | $60 | $52 | $40 | $51 |
| + Debt | $2 | $2 | $0 | $0 |
| Enterprise Value | $935 | $1,667 | $1,194 | $983 |
| Revenue | $33 | $16 | $8 | $87 |
| % Growth | 106.8% | 97.1% | -90.8% | – |
| Gross Profit | $24 | $11 | $4 | $83 |
| % Margin | 74.8% | 68.3% | 49.3% | 95.5% |
| EBITDA | -$49 | -$45 | -$37 | $47 |
| % Margin | -150.1% | -283.8% | -462.8% | 54.5% |
| Net Income | -$51 | -$45 | -$34 | $50 |
| % Margin | -157.4% | -285.6% | -425.7% | 57.7% |
| EPS Diluted | -0.52 | -0.46 | -0.35 | 0.51 |
| % Growth | -13% | -31.4% | -168.6% | – |
| Operating Cash Flow | -$47 | -$40 | -$41 | $42 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$47 | -$40 | -$41 | $42 |